Results 1 to 10 of about 30,272 (291)

Application and prospects of genetic engineering in CAR-NK cell therapy [PDF]

Frontiers in Immunology
With the rapid advancement of genetic engineering technologies, CAR-NK cell therapy, as an emerging immunotherapeutic approach, has demonstrated significant potential.
Caidong Hu, Wenhong Lai, Bin Tian, Xi Xu, Shuiling Xie, Wenting Zhong, Huiqiang Kang, Xiaoyun Chen, Hailiang Li, Jingxin Xu, Liping Liu   +10 more
doaj   +5 more sources

2B4 co-stimulation and dasatinib modulation enhance anti-CD19 CAR-NK-92 cell cytotoxicity [PDF]

Frontiers in Immunology
IntroductionChimeric Antigen Receptor (CAR)–based therapies have transformed cancer treatment, especially in hematological malignancies. While the impact of co-stimulatory domains on CAR-T cell efficacy is well established, the optimal signaling modules ...
Matheus Henrique dos Santos, Júlia Teixeira Cottas de Azevedo, Mara Elisama da Silva Januário, Dayane de Fátima Schmidt, Mariane Cariati Tirapelle, Alison Felipe Bordini Biggi, Sima Ebrahimabadi, Renata Nacasaki Silvestre, Dimas Tadeu Covas, Rodrigo T. Calado, Rodrigo T. Calado, Virgínia Picanço-Castro   +11 more
doaj   +2 more sources

Construction of anti-HER2 affibody-directed CAR-NK and its synergistic effects with doxorubicin-loaded nanodrug against HER2-positive breast cancer [PDF]

Frontiers in Immunology
IntroductionChimeric antigen receptor (CAR)-engineered T or natural killer (NK) cells are a promising approach for cancer immunotherapy. The leading region of the CAR structure is generally a single-chain antibody (scFv) fragment specific for a tumor ...
Xuesong He, Xuesong He, Zhaoyuan Liang, Qing Liu, Xiaofei Zhang, Hao Liang, Runqing Jia, Wang Sheng   +7 more
doaj   +2 more sources

Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells [PDF]

Molecular Therapy: Oncology
Natural killer (NK) cells have the intrinsic ability to kill cancer cells and are thus targeted in immunotherapy. Anti-CD19 CAR NK cells have shown efficacy in clinical studies in treating B cell malignancies; however, the full cytotoxic capacities of ...
Juliane Mietz, Lukas Egli, Meike Misiune, Arianna Picozzi, Nicolò Coianiz, Danielle Thompson, Marianna Ponzo, Alisson Charmey, Beat Bornhauser, Chiara F. Magnani, Christian Münz, Obinna Chijioke   +11 more
doaj   +2 more sources

Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells [PDF]

Frontiers in Immunology
While immunotherapy faces obstacles, the emergence of chimeric antigen receptor (CAR) engineered natural killer (NK) cells is paving new ways and might become a preferred option over CAR T cells very soon.
Jun-Hui Guo, Ali Afzal, Ali Afzal, Sadia Ahmad, Ghazala Saeed, Amna Rehman, Umair Ali Khan Saddozai, Umair Ali Khan Saddozai, Lei Liu, Shi-Hao Guo, Xin-Ying Ji, Xin-Ying Ji, Muhammad Babar Khawar, Muhammad Babar Khawar, Muhammad Babar Khawar   +14 more
doaj   +2 more sources

Signaling intact membrane-bound IL-15 enables potent anti-tumor activity and safety of CAR-NK cells [PDF]

Frontiers in Immunology
BackgroundChimeric antigen receptor (CAR)-NK cells are a promising and safe alternative to CAR-T cells. However, the limited persistence in vivo restricts their clinical application and sustained therapeutic responses.
Xiaodi Xu, Peiyu Cao, Meng Wang, Meng Wang, Meng Wang, Yan Wan, Shuwen Sun, Yuxin Chen, Yuxin Chen, Yuxin Chen, Yilin Liu, Tong Su, Tong Su, Tong Su, Ge Gao, Ge Gao, Ge Gao, Xinze Liu, Weixiang Zhong, Xi Chen, Xiaoyuan Lu, Buze Chen, Buze Chen, Junnian Zheng, Junnian Zheng, Gang Wang, Gang Wang, Gang Wang, Huizhong Li, Huizhong Li, Huizhong Li   +30 more
doaj   +2 more sources

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells

Advanced Science, 2023
The robust and stable expression of CD38 in T‐cell acute lymphoblastic leukemia (T‐ALL) blasts makes CD38 chimeric antigen receptor (CAR)‐T/natural killer (NK) a potential therapy for T‐ALL. However, CD38 expression in normal T/NK cells causes fratricide
Chan Liao, Yajie Wang, Yanjie Huang, Yanting Duan, Yan Liang, Jiangqing Chen, Jie Jiang, Kai Shang, Chun Zhou, Ying Gu, Nan Liu, Xun Zeng, Xiaofei Gao, Yongmin Tang, Jie Sun   +14 more
doaj   +1 more source

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies

Frontiers in Oncology, 2021
The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy.
Hui Lu, Xiaoyan Zhao, Ziying Li, Yu Hu, Huafang Wang   +4 more
doaj   +1 more source

NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells

Frontiers in Immunology, 2022
Dominant inhibitory receptors for HLA class I (HLA-I) endow NK cells with high intrinsic responsiveness, a process termed licensing or education, but hinder their ability to kill HLA-I+ tumor cells. Cancer immunotherapy with adoptive transfer of NK cells
Xiaoxuan Zhuang, Eric O. Long
doaj   +1 more source

ENHANCED ANTI-TUMOR ACTIVITY OF CD19.CAR-NK CELLS BY INCORPORATING IL-27

Hematology, Transfusion and Cell Therapy, 2023
Autologous T-cells expressing Chimeric Antigen Receptor (CAR) have shown great efficacy against hematologic malignancies, however, severe side effects limit their clinical use.
AFB Biggi, RN Silvestre, JTC Azevedo, MC Tirapelle, KCR Malmegrim, ML Figueiredo, DT Covas, V Picanço-Castro   +7 more
doaj   +1 more source